期刊文献+

左旋卡尼汀对维持性血液透析患者生活质量和贫血的影响 被引量:1

Effects of L-carnitine on health-related quality of life and anemia in maintenance hemodialysis patients
下载PDF
导出
摘要 目的探讨左旋卡尼汀对维持性血透(MHD)患者生活质量和贫血的影响。方法将30例维持性血透患者随机分为治疗组(15例)和对照组(15例)。两组透析结束后均使用重组人促红细胞生成素(rhFPO)3000IU皮下注射2~3次/周,而治疗组每次透析后加静脉注射左旋卡尼汀1g。随访12周,分别在治疗前及治疗12周末给两组患者应用SF36系统进行生活质量评分并检测血红蛋白、红细胞压积、血浆白蛋白的情况。结果治疗后治疗组患者的生活质量评分较治疗前有明显的上升,较对照组治疗后亦有明显的增高,差异均有统计学意义(P〈0.01);治疗组的血红蛋白、血细胞比容、血浆白蛋白水平显著高于对照组,差异有统计学意义(P〈0.01)。结论静脉注射左旋卡尼汀可明显提高维持性血透患者生活质量和促进改善维持性血液透析患者的贫血。 Objective To investigate the effect of L-carnitine on quality of life and anemia in maintenance hemodialysis(MItD) patients. Methods Thirty MHD patients were randomly divided into treatment group( n = 15) and control group( n = 15). All of the patients were received 30001U of rhEPO subcutaneous injection, 2 to 3 times a week after hemodialysis. In treatment group, 1.0g of L earnitine was infused to the patients at the end of each dialysis treatment for 12 weeks. SF36( Short Form with 36 questions)score about LQ were recorded and analyzed. Hb, Hct and Alb were measured before and after treatment. Results In treatment group each item was significantly increased after treatment (P 〈 0.05 ) while no significant changes was found in control group. Conclusion Using L-camitine may improve quality of life and anemia in MHD patients.
作者 徐小琳
出处 《中国临床新医学》 2009年第2期156-158,共3页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词 左旋卡尼汀 血液透析 生活质量 贫血 L-earnitine Hemodialysis Quality of life Anemia
  • 相关文献

参考文献6

二级参考文献21

  • 1周亦伦,刘惠兰,段晓峰.维持性血液透析患者铁状况的评价[J].中国血液净化,2002,1(2):18-21. 被引量:1
  • 2王根荣,冯菡芳,侯积寿.含α-酮酸的复方氨基酸治疗慢性肾功能不全[J].新药与临床,1995,14(2):124-125. 被引量:7
  • 3Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Ann Rev Nutr, 1986,6: 41-66.
  • 4Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. Ann Rev Nutr, 1998,18:39 61.
  • 5Bellinghieri G, Santoro D, Calvani M, et al. Carnitine and hemodialysis. Am J Kidney Dis, 2003,41 (3 suppl 1 ): S116-S122.
  • 6Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis,2003,41(4 suppl 4) :S13-S26.
  • 7Evans AM, Faull R, Fornasini G, et al. Pharmacokinetics of Lcarnitine in patients with end-stage renal disease undergoing long term hemodialysis. Clin Pharmacol Ther, 2000,68:238-249.
  • 8Brass EP, Adler S, Sietsema KE, et al. Intravenous L-carnitineincreases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis, 2001,37:1018-1028.
  • 9Matsumoto Y, Amano I, Hirose S, et al. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif,2001,19:24-32.
  • 10Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther, 1995, 17: 176-185.

共引文献42

同被引文献10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部